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ABSTRACT
Introduction: Coronary flow velocity reserve
(CFVR) is an important prognostic marker in
patients with stable coronary artery disease
(CAD). Beta-blockers and ivabradine have been
shown to improve CFVR in patients with stable
CAD, but their effects were never compared.
The aim of the current study was to compare
the effects of bisoprolol and ivabradine on
CFVR in patients with stable CAD.
Methods: Patients in sinus rhythm with stable
CAD were enrolled in this prospective,
randomized, double-blind trial. Patients had to
be in a stable condition for at least 15 days
before enrollment, on their usual therapy.
Patients who were receiving beta-blockers or
ivabradine entered a 2-week washout period
from these drugs before randomization.
Transthoracic Doppler-derived CFVR was
assessed in left anterior descending coronary
artery, and was calculated as the ratio of
hyperemic to baseline diastolic coronary flow
velocity (CFV). Hyperemic CFV was obtained
using dipyridamole administration using
standard protocols. After CFVR assessment,
patients were randomized to ivabradine or
bisoprolol and entered an up-titration phase,
and CFVR was assessed again 1 month after the
end of the up-titration phase.
Results: Fifty-nine patients (38 male, 21 female;
mean age 69 ± 9 years) were enrolled.
Transthoracic Doppler-derived assessment of
CFV and CFVR was successfully performed in all
patients. Baseline characteristics were similar
between the bisoprolol and ivabradine groups.
No patient dropped out during the study. At
baseline, rest and hyperemic peak CFV as well as
CFVR was not significantly different in the
ivabradine and bisoprolol groups. After the
therapy, resting peak CFV significantly
decreased in both the ivabradine and bisoprolol
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groups, but there was no significant difference
between the groups (ivabradine group 20.7 ± 4.6
vs. 22.8 ± 5.2, P\0.001; bisoprolol group
20.1 ± 4.1 vs. 22.1 ± 4.3, P\0.001). However,
hyperemic peak CFV significantly increased in
both groups, but to a greater extent in patients
treated with ivabradine (ivabradine: 70.7 ± 9.4
vs. 58.8 ± 9.2, P\0.001; bisoprolol: 65 ± 8.3 vs.
58.7 ± 8.2, P\0.001). Accordingly, CFVR
significantly increased in both groups
(ivabradine 3.52 ± 0.64 vs. 2.67 ± 0.55,
P\0.001; bisoprolol 3.35 ± 0.70 vs. 2.72 ± 0.55,
P\0.001), but it was significantly higher in
ivabradine group, despite a similar decrease in
heart rate (63 ± 7 vs. 61 ± 6; P not significant).
Conclusion: Ivabradine improves hyperemic
peak CFV and CFVR to a greater extent than
bisoprolol in patients with stable CAD, despite a
similar decrease in heart rate. These data
demonstrate that the benefits from ivabradine
therapy go beyond the heart rate. This could be
due to a different mechanism such as diastolic
perfusion time, isovolumic ventricular
relaxation, end-diastolicpressure, andcollaterals.
Funding: Servier.
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INTRODUCTION
Elevated resting heart rate (HR) is considered a
marker of cardiovascular risk in the general
population and in patients with cardiovascular
diseases. It is associated with a risk of
cardiovascular morbidity and mortality in
healthy populations [1], and in patients with
hypertension [2], coronary artery disease (CAD)
[3], and chronic heart failure (HF) [4–6]. This
negative prognostic value of a higher HR
appears to be independent of traditional
cardiovascular risk factors [1, 3, 4, 6, 7].
Some HR-lowering agents have been shown
to improve clinical outcomes, although
whether HR reduction is the only mechanism
of benefit is hard to demonstrate and could be
reductive. Ivabradine reduces the HR without
affecting blood pressure or left ventricular
systolic function by inhibiting the If current in
the sinoatrial node. In patients with CAD and
left ventricular systolic dysfunction, it is shown
to reduce hospitalization for coronary
revascularization and myocardial infarction
(MI) [8]. Moreover, it was able to improve
outcomes in patients who had a HR of
70 beats per minute (bpm) or more.
Coronary flow velocity reserve (CFVR) is
defined as the ratio of hyperemic to basal peak
velocity flow and reflects the functional
capacity of adaptation of coronary
microcirculation during cardiac work. It
depends on the combined effects of epicardial
coronary stenosis and microvascular
dysfunction. Transthoracic Doppler
echocardiography (TTDE) allows non-invasive
assessment of CFVR in the left anterior
descending coronary artery (LAD) [9–12].
TTDE-derived CFVR measurement is not only
useful to diagnose obstructive coronary artery
narrowing [13, 14], but is also useful to assess
microvascular function [15, 16].
Previous reports have shown that reduced
CFVR is an important prognostic marker in
patients with non-obstructive CAD [17–20].
Beta-blockers and ivabradine have been shown
to improve CFVR in patients with stable CAD
[21–23], but their effects were never compared.
The aim of the current study was to compare
the effect of bisoprolol and ivabradine on CFV
and CFVR in patients with stable CAD, and to
better understand the effect of these drugs on
coronary flow.
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METHODS
Trial Design
This prospective, randomized, double-blind trial
enrolled patients in sinus rhythm with stable
CAD. Stable CAD was defined as previous MI at
least 6 months before randomization, previous
surgical or percutaneous revascularization (at
least 6 months) or angiographic evidence of at
least 50%narrowing ofC1major coronary vessel.
Exclusion criteria were: unlikely cooperation
in the study; pregnancy or breastfeeding; recent
(\6 months) MI or coronary revascularization;
history of stroke or cerebral transient ischemic
attack (\3 months); scheduled surgical or
percutaneous revascularization; at least one
criterion among implanted pacemaker or
cardioverter defibrillator, scheduled surgery for
valvular disease, sick sinus syndrome, sinoatrial
block, congenital long QT, complete
atrioventricular block and severe or
uncontrolled hypertension (systolic blood
pressure [180 mmHg and/or diastolic blood
pressure[110 mmHg).
After providing written informed consent,
patients entered a 2-week washout phase from
beta-blocker or ivabradine therapy to confirm
eligibility and clinical stability. At the end of
the run-in phase, patients had to be more than
18 years old, in sinus rhythm with resting HR
C60 bpm, preserved left ventricular ejection
fraction (C50%), and in a stable condition for
at least 15 days.
If eligibility and clinical stability were
confirmed during the run-in phase, patients
were randomly assigned, in a double-blind
protocol, to receive either ivabradine at a
starting dose of 2.5 mg twice daily or
bisoprolol at a starting dose of 1.25 mg twice
daily. Both drugs were weekly up-titrated,
according to the HR, to the highest tolerated
dose (maximum dosage: 7.5 mg twice daily for
ivabradine and 5 mg twice daily for bisoprolol).
After up-titration phase, patients received
ivabradine or bisoprolol for another month.
Patients were to receive stable background
therapy according to contemporary guidelines.
The study was approved by internal Ethics
Committee. All procedures followed were in
accordance with the Helsinki Declaration of
1964, as revised in 2013.
Coronary Flow Reserve
Transthoracic Doppler-derived assessment of
CFV and CFVR was performed at baseline and
after 1 month of treatment, using a VividTM 7
ultrasound system (GE Healthcare). Coronary
flow was assessed in the distal tract of the LAD
using a modified apical two-chamber view. Peak
diastolic velocity was measured at baseline and
after dipyridamole infusion (0.84 mg/kg over
6 min), as envisaged by a well-established
protocol [24, 25]. Baseline and hyperemic peak
diastolic velocities were obtained from three
consecutive cardiac cycles, and CFVR was
calculated as the ratio of hyperemic to
baseline peak diastolic velocity.
All measurements were performed offline,
using EchoPACTM Clinical Workstation
Software (GE Healthcare), by two experienced
echocardiographers, blinded to all clinical data.
The intra- and inter-observer variability of
measurements was 4% and 6%, respectively,
and was assessed in 10 consecutive patients.
Statistical Analysis
The baseline characteristics are shown as means
and standard deviations for continuous
variables and as numbers and percentages for
categorical variables. Unpaired t test was used to
analyze differences in continuous variables
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among groups; paired t test was used to analyze
differences within groups. Analysis of
categorical data was performed using the
Chi-squared test. All tests of hypotheses were
two-sided and a P value\0.05 was considered
statistically significant. SPSS Statistics Software
(V22.0, IBM, NY, USA) was used for statistical
analysis.
RESULTS
In total, 59 patients (38 male, 21 female) were
enrolled in the study. Baseline characteristics
were similar in the two groups (Table 1). The
study population had a mean age of
69 ± 9 years (35.6% female), and a resting HR
of 72.2 ± 9.3 bpm. Overall, 22% of the patients
had a previous MI, 36% had previous coronary
revascularization, while 34% had exertional
angina.
Twenty-four patients (41%) had
angiographic evidence of at least 50%
narrowing of C1 major coronary vessel: 11
patients had coronary stenosis of LAD (4
patients with narrowing between 70% and
80% were equally randomized to ivabradine or
bisoprolol to avoid bias), 9 patients of left
circumflex artery and 7 patients of right
coronary artery.
Patients were already receiving appropriate
therapy for CAD, according to contemporary
guidelines, when enrolled in the trial.
The average dosage of the drugs was
6.3 ± 1.1 mg twice daily in the ivabradine
group and 5.8 ± 0.8 mg twice daily in the
bisoprolol group. One month after the end of
the up-titration phase, mean HR significantly
decreased, as expected, in both groups, without
significant differences between the groups
(from 73 ± 10 to 63 ± 7 bpm in ivabradine
Table 1 Baseline clinical characteristics
Characteristic Ivabradine Bisoprolol P
Age (years), mean ± SD 70 ± 7 68 ± 7 ns
Gender (women), n (%) 10 (33) 11 (37) ns
BMI (kg/m2), mean ± SD 23.6 ± 4,2 24.1 ± 4,1 ns
Hypertension, n (%) 20 (66) 18 (62) ns
Diabetes, n (%) 4 (13) 4 (14) ns
Smoking, n (%) 7 (23) 7 (24) ns
Dyslipidemia, n (%) 14 (46) 12 (41) ns
Previous MI, n (%) 7 (23) 6 (21) ns
Previous revascularization, n (%) 10 (33) 11 (38) ns
Exertional angina, n (%) 11 (36) 9 (31) ns
SBP (mmHg), mean ± SD 126 ± 11 129 ± 14 ns
DBP (mmHg), mean ± SD 74 ± 7 77 ± 8 ns
Resting heart rate (bpm), mean ± SD 73 ± 10 71 ± 9 ns
LVEF (%), mean ± SD 58 ± 6 60 ± 5 ns
BMI Body mass index, bpm Beats per minute, DBP Diastolic blood pressure, LVEF Left ventricular ejection fraction, MI
Myocardial infarction, ns Not signiﬁcant, SBP Systolic blood pressure, SD Standard deviation
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group, P\0.001; from 71 ± 9 to 61 ± 6 bpm in
bisoprolol group, P\0.001; Table 2).
Dipyridamole infusion was well tolerated and
CFVR was successfully performed in all patients.
Doppler parameters of CFV and CFVR are
given in Table 2. At baseline, rest and
hyperemic peak CFV as well as CFVR was not
significantly different in the ivabradine and
bisoprolol groups. After therapy, resting peak
CFV significantly decreased in both the
ivabradine and bisoprolol groups, but without
significant difference among them. However,
hyperemic peak CFV significantly increased in
both groups, but to a greater extent in the
ivabradine group. Accordingly, CFVR
significantly increased in both groups, but to a
greater extent in the ivabradine group (Fig. 1).
All of these results were obtained despite a
similar lowering of HR (63 ± 7 vs. 61 ± 6 bpm,
P not significant; Table 2; Fig. 2). None of the
patents dropped out during the study.
DISCUSSION
This study demonstrated that ivabradine
increases hyperemic CFV and CFVR to a
greater extent than bisoprolol, despite a
similar HR reduction. The mechanism
underlying differences between ivabradine and
beta-blockers on CFV and CFVR is hypothetical,
but extremely intriguing.
Resting HR is an important and independent
risk factor, with important prognostic
implications, as a predictor for cardiovascular
mortality andmorbidity, independently of other
risk factors [1–7]. Thus, several pharmacological
treatments have been proposed to reduce HR and
improve the outcome of patients with CAD and
HF. However, it can be reductive to say that every
effect of these drugs is only due to HR reduction.
Ivabradine is a selective inhibitor of the If
channel, first described by Thollon et al. [26] in
1997. Inhibiting the f (‘‘funny’’) channel, which
controls the electrical pacemaker activity in the
Table 2 Doppler parameters and heart rate before and after treatment
Parameter Ivabradine Bisoprolol
Before treatment
Baseline diastolic ﬂow velocity (cm/sec) 22.8 ± 5.2 22.1 ± 4.3
Hyperemic diastolic ﬂow velocity (cm/sec) 58.8 ± 9.2 58.7 ± 8.2
Coronary ﬂow reserve 2.67 ± 0.55 2.72 ± 0.55
Heart rate (bpm) 73 ± 10 71 ± 9
After treatment
Baseline diastolic ﬂow velocity (cm/sec) 20.7 ± 4.6* 20.1 ± 4.1*
Hyperemic diastolic ﬂow velocity (cm/sec) 70.7 ± 9.4*,# 65.0 ± 8.3*
Coronary ﬂow reserve 3.52 ± 0.64*,# 3.35 ± 0.70*
Heart rate (beats/min) 63 ± 7* 61 ± 6*
Data are presented as mean ± standard deviation
bpm Beats per minute
* P\0.01 vs. same group before treatment
# P\0.01 vs. bisoprolol
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sinoatrial node, ivabradine induces a decrease
in HR in patients with sinus rhythm, both at
rest and with exercise. Bradycardia prolongs
diastole and improves ventricular filling, which
leads to lesser myocardial oxygen consumption
and allows increased coronary flow and
myocardial perfusion [27]. Unlike other
rate-reducing agents like beta-blockers or
calcium channel blockers, ivabradine does not
decrease systemic blood pressure [28], does not
Fig. 1 Coronary ﬂow reserve at baseline (blue) and after (yellow) therapy
Fig. 2 Effects of bisoprolol and ivabradine on resting heart rate (bpm). Baseline (blue), after treatment (yellow). ns Not
signiﬁcant
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suppress myocardial contractility [28, 29], and
does not cause atrioventricular conduction
abnormalities [30]. Specifically, it does not
alter QT interval or repolarization duration as
well as conductivity or refractoriness of
ventricles, His-Purkinje system, atrioventricular
node and atrium [30]. Four isoforms of the If
channel gene were identified in the animal
hearts [31, 32], and HCN2, whose levels are
higher in the sinus node [33], is considered to
be the dominant isoform.
Ivabradine reduces theentryof sodiumintothe
myocytes, with consequent reduction of cytosolic
calcium, and improves the reuptake of calcium by
the sarcoplasmic reticulum, leading to an
improvement of ventricular relaxation [34, 35].
Ivabradine and Beta-Blockers
Ivabradine and beta-blockers, as their
HR-lowering effects, are often still considered
‘‘similar’’ drugs. In large clinical trials,
ivabradine has been investigated as an
alternative to beta-blockers, when these agents
cannot be tolerated or are contraindicated, or in
addition, when HR is not adequately controlled
with the highest tolerated dose of beta-blockers.
But we should wonder if their effect is really
so similar. Recently, multiple mechanisms have
been proposed to explain differences between
ivabradine and beta-blockers. Several
experimental studies reported a beneficial
effect of ivabradine that was at least in part
HR independent and supported the so-called
‘‘pleiotropic actions’’ of ivabradine [36–39].
Thus, which is the key to better understand
the differences between ivabradine and
bisoprolol on coronary flow?
Coronary blood flow occurs mostly during
diastole, when there is a reduced compression
of the coronary vessels by the surrounding
muscular cardiac fibers as compared to the
systolic period. It is clear that diastolic
perfusion time mainly affects subendocardial
blood flow. Furthermore, coronary flow can be
affected by the pressure gradient between mean
diastolic pressure in the aortic root and diastolic
ventricular pressure. This pressure gradient and
the duration of the diastole are integrated into
the diastolic pressure–time integral [40], and
anything that modifies the diastolic
pressure–time integral will modify coronary
blood flow: it is here that we can find the key
of the differences between ivabradine and
bisoprolol on coronary blood flow.
The effects of ivabradine and atenolol, a
beta-blocker, on diastolic time have been
compared in two experiments [41, 42].
Ivabradine increased diastolic time both at rest
and during treadmill exercise to a greater degree
than atenolol, though HR was similar with both
drugs. As a result, ivabradine causes a greater
increase in coronary blood flow at exercise for
the same reduction in HR compared with
beta-blockers (as demonstrated in
experiments), because of the greater
prolongation of diastolic filling time of
coronary arteries.
Beta-blockers, with their negative lusitropic
action, in contrast to ivabradine, impair
isovolumic ventricular relaxation, offsetting
part of the benefits of prolonged diastolic
duration, and this may be another reason for
the difference between ivabradine and
bisoprolol on CFV and CFVR [43].
Moreover, with ivabradine there is not an
increase or unmasking of alpha-adrenergic
coronary vasoconstriction, compared with
beta-blockers, in the epicardial coronary
arteries and even more in the coronary
microcirculation [44].
Finally, the development of collateral
circulation represents a natural mechanism to
compensate for the limitation of coronary flow
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with progression of coronary stenosis and is
advantageous protection tissue from ischemia.
Patel et al. [45] demonstrated that there is an
association between bradycardia and growth of
collateral vessels in patients with obstructive
CAD. It was suggested that HR-reducing agents
might be useful for promoting the development
of coronary collaterals in patients with
atherosclerotic disease. Recently, Gloekler
et al. [46] assessed the effect of ivabradine on
the human coronary collateral circulation. The
results of this first-time clinical,
placebo-controlled randomized study
demonstrated that ivabradine improves
coronary collateral function in patients with
stable CAD. Theoretically, improved coronary
collateral function could affect Doppler-derived
coronary flow reserve, although specific trials
should confirm this hypothesis.
Limitations
Not all patients underwent coronary
angiography just before enrollment. A small
study population was included and,
accordingly, no statistical data on clinical
endpoints were obtained. Moreover, no data
on any subsequent revascularization were
collected as follow-up was closed after
coronary flow assessment.
CONCLUSIONS
This study shows for thefirst time inhumans that
ivabradine significantly improves hyperemic
peak CFV and CFVR to a greater extent than a
beta-blocker, in patients with stable CAD,
demonstrating that ivabradine not only has an
anti-anginal but also an anti-ischemic effect.
Similar HR reduction obtained with both drugs
implies that the effect of ivabradine treatment
goes beyond the HR. Differences between
ivabradine and bisoprolol could be due to a
different effect on diastolic perfusion time and
isovolumic ventricular relaxation, as well as
unmasking of alpha-adrenergic coronary
vasoconstriction by beta-blockers. Theoretically,
an overall improvement of diastolic function and
a positive effect on coronary collateral function
could further explain differences between
ivabradine and beta-blockers on CFV and CFVR.
The next questions that the medical community
has to answer are as follows:Does ivabradinehave
anadvantageoverbeta-blockers?Does ivabradine
have other therapeutic effects beyond HR
reduction that make it a preferable agent?
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